William Rand, MD
Ophthalmology · Pompano Beach, FLNPI 1295829927
Payments from drug & device makers
Across 50 payments — averaging $1748.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$72K
- Carl Zeiss Meditec, Inc.$8K
- AbbVie$4K
- Aerie Pharmaceuticals, Inc.$2K
- Mallinckrodt Hospital Products Inc.$138
- Genentech, Inc.$129
- plus $184 from 7 others
Across 779 payments — averaging $482.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$316K
- Genentech, Inc.$40K
- Eyepoint US, Inc.$19K
- AbbVie$1K
What the payments were for
- Food & beverage$3753%
- Education$5,28838%
- Gifts$8,08359%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 23 | $72,238 |
| Carl Zeiss Meditec, Inc. | 1 | $8,083 |
| AbbVie(2 entities) | 7 | $4,429 |
| Aerie Pharmaceuticals, Inc. | 5 | $2,241 |
| Mallinckrodt Hospital Products Inc. | 3 | $138 |
| Genentech, Inc. | 2 | $129 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $41 |
| Heidelberg Engineering, Inc. | 1 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,443 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 120 | $103,515 |
| LumiganBimatoprost | 68 | $31,215 |
| CombiganBrimonidine Tartrate/Timolol | 81 | $29,560 |
| XiidraLifitegrast | 27 | $23,514 |
| Prednisolone Acetate | 669 | $21,183 |
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $19,634 |
| VyzultaLatanoprostene Bunod | 27 | $11,480 |
| Fluorometholone | 79 | $8,826 |
| Alphagan PBrimonidine Tartrate | 23 | $8,673 |
| Latanoprost | 1,163 | $8,637 |
| Ketorolac Tromethamine | 393 | $8,501 |
| Brimonidine Tartrate | 621 | $6,288 |
| Brinzolamide | 24 | $6,224 |
| Cyclosporine | 19 | $6,067 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $4,429 | $172,962292 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $24 | $34,99454 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $2,241 | $19,63450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Pompano Beach
- Carl DanzigPompano Beach$5.3M
- Shani ReichPompano Beach$502K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.